速递 | 抗肥胖的基因“万里挑一”，这款疗法有望模拟神奇基因突变
▎药明康德内容团队编辑
参考资料:
[1] AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity. Retrieved July 27, 2021, from https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-regeneron-to-research-develop-and-commercialise-new-small-molecule-medicines-for-obesity.html
[2] Regeneron's latest genetics discovery hooks AstraZeneca — now all-in on developing small molecules for obesity. Retrieved July 27, 2021, from https://endpts.com/regenerons-latest-genetics-discovery-hooks-astrazeneca-now-all-in-on-developing-small-molecules-for-obesity/
[3] AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics. Retrieved July 27, 2021, from https://www.fiercebiotech.com/biotech/astrazeneca-teams-up-regeneron-for-obesity-busting-drug-pact-focused-genetics
[4] Parsa Akbari et al., (2021) Sequencingof 640,000 exomes identifies GPR75 variants associated with protection fromobesity. Science DOI: 10.1126/science.abf8683
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。